The treatment of IBD is currently suboptimal. Continuous monitoring of patients with IBD, patient engagement and early treatment adjustments are still difficult hurdles. E-Health could be an efficient tool to improve these aspects, but the current evidence for its use in IBD is poor. An integrated cost-effective e-health system supported by a stable legal framework is eagerly needed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement
BMC Psychology Open Access 28 November 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pew Research Center. Three technology revolutions. PewInternet http://www.pewinternet.org/three-technology-revolutions/ (2017).
FDA. FDA permits marketing of first system of mobile medical apps for continuous glucose monitoring. FDA http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm431385.htm (2015).
Madara, J. L. Digital dystopia. American Medical Association https://www.ama-assn.org/sites/default/files/media-browser/public/meeting/Madera-speech-annual-2016.pdf (2016).
Jackson, B. D. et al. Ehealth technologies in inflammatory bowel disease: a systematic review. J. Crohns Colitis 10, 1103–1121 (2016).
Mistry, H., Garnvwa, H. & Oppong, R. Critical appraisal of published systematic reviews assessing the cost-effectiveness of telemedicine studies. Telemed. J. E. Health 20, 609–618 (2014).
Han, J. H. et al. Professional practice and innovation: chronic disease, geographic location and socioeconomic disadvantage as obstacles to equitable access to e-health. HIM J. 39, 30–36 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.B. is part of the advisory board for Dr Falk Benelux, Hospira, Janssens-Cilag, MSD, Mundipharma, Pfizer, Roche and Takeda, has received lecture fees from Abbvie, Takeda and Vifor Pharma, and has received an educational grant from Abbvie. L.P.-B. has received consulting fees from Abbvie, Amgen, Biogaran, BMS, Boerhinger-Ingelheim, Celgene, Celltrion, Ferring, Forward Pharma, Genentech, HAC-Pharma, Hospira, Index Pharmaceuticals, Janssen, Lilly, Merck, Mitsubishi, Norgine, Pfizer, Pharmacosmos, Pilège, Sandoz, Takeda, Therakos, Tillots, UCB-pharma and Vifor; received lecture fees from Merck, Abbvie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi, HAC-pharma. L.P. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Bossuyt, P., Pouillon, L. & Peyrin-Biroulet, L. Primetime for e-health in IBD?. Nat Rev Gastroenterol Hepatol 14, 133–134 (2017). https://doi.org/10.1038/nrgastro.2017.11
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.11
This article is cited by
-
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement
BMC Psychology (2021)
-
Big data in IBD: a look into the future
Nature Reviews Gastroenterology & Hepatology (2019)
